Verdemed Company Profile

Background

Verdemed Holdings Inc. is a Canadian pharmaceutical company specializing in the development and commercialization of cannabis-based medications across Latin America. Established in 2018 and headquartered in Toronto, Verdemed's mission is to enhance patient health by providing accessible, high-quality cannabinoid pharmaceuticals. The company operates in key Latin American markets, including Brazil, Chile, Colombia, Mexico, and Peru, aiming to bridge the gap between North American cannabis innovations and the unmet medical needs in these regions.

Key Strategic Focus

Verdemed's strategic focus centers on:

• Product Development: Formulating and registering cannabinoid-based medications tailored to the regulatory landscapes of Latin American countries.

• Market Expansion: Establishing a robust presence in major Latin American markets by navigating complex regulatory environments and building local partnerships.

• Regulatory Compliance: Ensuring all products meet the stringent standards set by regional health authorities, such as Brazil's Anvisa and Peru's DIGEMID.

• Clinical Research: Conducting clinical trials to validate the efficacy and safety of its products, thereby fostering trust among healthcare professionals and patients.

Financials and Funding

Since its inception, Verdemed has successfully raised significant capital to fuel its growth:

• Seed Funding (2018): Secured US$650,000 from Brazilian and Colombian investors.

• Series A (2019): Raised US$12 million from qualified Latin American private investors, allocated in two tranches: an initial US$6 million in convertible debt and a subsequent US$6 million in equity.

• Series B (2019): Announced plans to raise an additional US$9 million, including a US$3 million lead order from existing backers, to advance drug development and expand cultivation operations.

• Subsequent Rounds (2023): Initiated a new investment round aiming to raise US$1.5 million to bolster production, distribution, and sales capabilities in Brazil.

These funds have been strategically utilized for acquisitions, product development, regulatory compliance, and market expansion initiatives.

Pipeline Development

Verdemed's product pipeline includes:

• Canabidiol Verdemed: Available in concentrations ranging from 20 mg/ml to 200 mg/ml, targeting conditions such as refractory pediatric epilepsy.

• CBD 100 Isolate: A formulation similar to Epidiolex, intended for the treatment of severe epilepsy.

• Nabiximol Full Spectrum: Comparable to Sativex, aimed at managing multiple sclerosis-related spasticity.

• Extended-Release CBD/THC Pills: Designed to address sleep disorders.

The company has received multiple approvals from Anvisa, positioning it as a leading provider of authorized cannabis-based medications in Brazil. Clinical trials are underway to further validate these products' efficacy and safety.

Technological Platform and Innovation

Verdemed leverages advanced scientific methodologies and proprietary technologies to develop its product portfolio:

• Proprietary Formulations: Developing unique cannabinoid-based formulations tailored to specific medical conditions prevalent in Latin America.

• Clinical Research: Conducting rigorous clinical trials to ensure product efficacy and safety, adhering to international standards.

• Regulatory Expertise: Navigating complex regulatory frameworks across multiple jurisdictions to expedite product approvals and market entry.

Leadership Team

Verdemed's leadership comprises seasoned professionals with diverse expertise:

• José Bacellar: President and CEO. Former CEO of Bombril in Brazil, with extensive experience in market regulation and cannabis medicinal products.

• Fabio Lampugnani: Managing Director. Oversees operations and strategic initiatives across Latin American markets.

• Dr. Paula Vinha: Medical Director. Leads medical affairs and clinical research programs.

• Dr. José Almeida: Director of Medical Marketing and Sales. Former CEO of NuNature and Pele Nova, responsible for market expansion and sales strategies.

Leadership Changes

In 2023, Verdemed strengthened its leadership team by appointing Dr. Paula Vinha as Medical Director and Dr. José Almeida as Director of Medical Marketing and Sales, enhancing the company's medical and commercial capabilities.

Competitor Profile

Market Insights and Dynamics

The Latin American medical cannabis market is experiencing rapid growth, driven by regulatory reforms and increasing acceptance of cannabis-based therapies. Brazil, with a population exceeding 200 million, represents a significant opportunity, with pharmacy sales surpassing BRL 100 million and a 93% surge in product imports via RDC 600/2022.

Competitor Analysis

Key competitors in the region include:

• Clever Leaves: A multinational operator with operations in Colombia and Portugal, focusing on large-scale cultivation and pharmaceutical-grade processing.

• Khiron Life Sciences: A Colombian-based company specializing in medical cannabis products and services, with a strong presence in Latin America.

• Canopy Growth: A Canadian cannabis company with investments in Latin American markets, aiming to establish a foothold in the region.

These competitors focus on cultivation, product development, and navigating regulatory landscapes to capture market share in Latin America.

Strategic Collaborations and Partnerships

Verdemed has established significant partnerships to enhance its market position:

• Clever Leaves: In 2021, Verdemed partnered with Clever Leaves to supply EU-GMP and INVIMA-certified CBD products for the Brazilian and Peruvian markets, expanding its product offerings and ensuring compliance with international quality standards.

• Greenfarma: Acquired a significant interest in this Colombian licensed producer, enabling vertical integration and control over the supply chain.

Operational Insights

Verdemed's strategic considerations include:

• Regulatory Navigation: Expertise in managing diverse regulatory environments across Latin America, providing a competitive edge.

• Product Differentiation: Offering a diverse portfolio of cannabinoid-based medications tailored to regional medical needs.

• Market Penetration: Establishing a strong presence in key markets through local partnerships and acquisitions.

Strategic Opportunities and Future Directions

Verdemed's roadmap includes:

• Product Expansion: Introducing additional cannabinoid-based medications to address unmet medical needs.

• Market Growth: Expanding into new Latin American countries, including Argentina, Mexico, and Peru, through acquisitions and joint ventures.

• Public Offering: Pursuing an IPO on the Toronto Stock Exchange to raise capital for further expansion and to enhance market visibility.

Contact Information

• Website: Verdemed's official site

• LinkedIn: Verdemed's LinkedIn page

• Twitter: Verdemed's Twitter handle

• Instagram: Verdemed's Instagram profile

• Facebook: Verdemed's Facebook page